Physician profile
Steven Alan Lerner
NPI 1518059237
$7,244.67
in general payments reported to CMS, 2019-2025
19 companies · $2,708 in 2025
The $2,708 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $409 · 2021: $1,269 · 2022: $884 · 2023: $855 · 2024: $706 · 2025: $2,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,602 · Grant: $1,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,601.83 |
| Grant | $1,666.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $1,826.00 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,593.50 | 2019-2025 | Xifaxan, Plenvu |
| Abbvie INC. | $1,220.84 | 2019-2025 | |
| Pfizer INC. | $558.08 | 2019-2025 | |
| Gilead Sciences, INC. | $542.92 | 2019-2025 | |
| Janssen Biotech, INC. | $294.41 | 2021-2025 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $234.83 | 2023-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $214.57 | 2021-2022 | |
| Capsovision, INC. | $203.05 | 2025 | Capsocam Plus |
| Braintree Laboratories, INC. | $145.65 | 2020-2022 | |
| Novo Nordisk INC | $145.22 | 2025 | Wegovy |
| Genzyme Corporation | $101.20 | 2023-2025 | |
| Redhill Biopharma INC. | $44.34 | 2021 | |
| Ferring Pharmaceuticals INC. | $25.93 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $25.51 | 2025 | Zenpep |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $18.83 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.43 | 2020 | |
| Echosens North America, INC. | $15.83 | 2025 | Fibroscan |
| Takeda Pharmaceuticals U.S.A., INC. | $15.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.